AyushSuraksha Portal launched address misleading advertisements and ADR

India Pharma Outlook Team | Tuesday, 03 June 2025

 AyushSuraksha Portal launched address misleading advertisements and ADR
  • AyushSuraksha Portal launched for ADRs and ad monitoring.
  • Enables real-time reporting, analysis, and inter-agency coordination.
  • Meets Supreme Court directive ahead of June 2025 deadline.

Following direction from the Supreme Court of India in July 2024, the Ministry of Ayush has introduced AyushSuraksha Portal to handle fake advertisements and report adverse drug reactions (ADRs), The AyushSuraksha Portal is a centralised platform developed with help from the Central Council for Research in Siddha (CCRS) to accomplish effective reporting of ADR and coordinate the action of various regulatory authorities with the help of the National Pharmacovigilance Programme.

Also read: Ensuring Data Privacy in Pharma World

The AyushSuraksha Portal is a centralised digital interface for timely reporting by citizens, health professionals, and regulators to report ADRs and for real-time tracking and regulatory action. The AyushSuraksha Portal is useful to bring various agencies together, such as CDSCO, Ministry of Information & Broadcasting, CCPA, FSSAI, and other State Licensing Authorities.

 “With the launch of the AyushSuraksha Portal, we are empowering citizens and professionals alike to become active participants in safeguarding the integrity of Ayush systems. This platform will serve as a vigilant watchtower against misleading advertisements and ensure that only safe and credible products reach the people,” said Union Minister of State (independent charge), Ministry of Ayush, Prataprao Jadhav, while launching the portal.   Vaidya Rajesh Kotecha, secretary, Ministry of Ayush, said, “The AyushSuraksha Portal represents a significant advancement in pharmacovigilance and regulatory convergence within the Ayush ecosystem. The portal facilitates real-time monitoring, systematic analysis, and coordinated action on misleading advertisements and adverse drug reactions by integrating data from State Licensing Authorities, national pharmacovigilance centers, and key regulatory stakeholders. We have made it accessible to the public so that any citizen can directly report misleading ads or ADRs via the portal.” 

© 2025 India Pharma Outlook. All Rights Reserved.